Ravi Vij, MD, MBA

Bone Marrow Transplant Specialist, Medical Oncologist

Primary Academic Title

Professor of Medicine, Division of Oncology, Section of Bone Marrow Transplantation, WashU Medicine

Clinical Expertise

As a member of our leukemia and myelodysplastic syndromes specialist teams, Dr. Vij cares for patients diagnosed with leukemia and lymphoma through treatment and recovery. Learn more about Dr. Vij and the Blood and Marrow Transplant Program at Siteman.

Research Interest

Clinical interest in stem-cell transplantation and the management of hematologic malignancy. I lead a multi-disciplinary research program focused on treatment of multiple myeloma.

Education

1989: MBBS, Maulana Azad Medical College, New Delhi, India

Board Certification

1996: American Board of Internal Medicine, Internal Medicine
1999: American Board of Internal Medicine, Medical Oncology
2000: American Board of Internal Medicine, Hematology

Selected Research Publications

Longitudinal Profiling of Tumor and Immune Compartments Uncovers Patterns of Dysregulation and Associations with Response in Multiple Myeloma.

Ohlstrom DJ, Pilcher WC, Michaud ME, [...] Vij R, [...] Bhasin MK
Blood Cancer Discov 2026

A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.

Pilcher WC, Yao L, Gonzalez-Kozlova E, [...] Vij R, [...] Bhasin M
Nat Cancer 2026

Blood-Based Measurable Residual Disease by Clonotypic Mass Spectrometry is Prognostic in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant.

Slade MJ, Fortier J, Khaled A, [...] Vij R
Clin Lymphoma Myeloma Leuk 2025

Chemo-RaST with bortezomib inhibits multiple myeloma relapse.

Ghai A, Zheleznyak A, Egbulefu C, [...] Vij R, [...] Achilefu S
Theranostics 2025

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.

Ailawadhi S, Arnulf B, Patel K, [...] Vij R, [...] Rodríguez-Otero P
Blood 2024

IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma.

Sun J, Corradini S, Azab F, [...] Vij R, [...] Azab AK
Leukemia 2024

A phase Ib trial of isatuximab, bendamustine, and prednisone in relapsed/refractory multiple myeloma.

Goldsmith SR, Slade MJ, Fiala M, [...] Vij R
Ann Hematol 2024

Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial.

Richard S, Lesokhin AM, Paul B, [...] Vij R, [...] Dhodapkar MV
Nat Cancer 2024

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.

Skerget S, Penaherrera D, Chari A, [...] Vij R, [...] Keats JJ
Nat Genet 2024

Mixed-Methods Study on the Responsiveness of the Comprehensive Score for Financial Toxicity Among People With Multiple Myeloma.

Fiala MA, Leblanc MR, Coccia KW, [...] Vij R
JCO Oncol Pract 2024

Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial.

Slade M, Fiala MA, Kirchmeyer M, [...] Vij R
Transplant Cell Ther 2023

Epigenetic regulation during cancer transitions across 11 tumour types.

Terekhanova NV, Karpova A, Liang WW, [...] Vij R, [...] Ding L
Nature 2023

Contact Information

Gary C. Werths Building at Siteman Cancer Center

4500 Forest Park Avenue
Saint Louis, MO 63108

Phone Numbers

Appointments: (314) 747-7222
Toll Free: (800) 600-3606

Request an appointment